Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jochen Klaus Maria Lennerz, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Jochen Lennerz and Dora Dias-Santagata.
Connection Strength

1.437
  1. Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. Thyroid. 2020 09; 30(9):1384-1389.
    View in: PubMed
    Score: 0.219
  2. Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Oncologist. 2019 10; 24(10):1356-1367.
    View in: PubMed
    Score: 0.202
  3. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.193
  4. Artificial Intelligence Approach for Variant Reporting. JCO Clin Cancer Inform. 2018; 2.
    View in: PubMed
    Score: 0.188
  5. Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. Int J Colorectal Dis. 2016 05; 31(5):973-982.
    View in: PubMed
    Score: 0.164
  6. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948.
    View in: PubMed
    Score: 0.116
  7. t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Adv. 2022 01 08; 6(3):818-827.
    View in: PubMed
    Score: 0.061
  8. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020 04 15; 26(8):1877-1885.
    View in: PubMed
    Score: 0.053
  9. Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization. Hum Pathol. 2019 11; 93:65-73.
    View in: PubMed
    Score: 0.052
  10. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol. 2019 04; 86:1-11.
    View in: PubMed
    Score: 0.050
  11. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
    View in: PubMed
    Score: 0.049
  12. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. Hum Pathol. 2019 01; 83:50-58.
    View in: PubMed
    Score: 0.048
  13. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.